Last reviewed · How we verify
Matching placebo nasal spray
A placebo nasal spray formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.
At a glance
| Generic name | Matching placebo nasal spray |
|---|---|
| Also known as | Placebo |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebo nasal sprays are inert formulations designed to mimic the appearance, taste, smell, and administration route of an active investigational drug while containing no therapeutic agent. They are used in blinded clinical trials to control for placebo effect and ensure valid efficacy and safety comparisons between treatment and control groups.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- Clinical Trial of Intranasal Delivery of NT-301 (PHASE1)
- Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in Acute Ischemic Stroke (PHASE1, PHASE2)
- Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults (PHASE2)
- Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia. (PHASE4)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo nasal spray CI brief — competitive landscape report
- Matching placebo nasal spray updates RSS · CI watch RSS
- Organon and Co portfolio CI